Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

• Status: Completed
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in gynecological cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Darbepoetin alfa; Epoetin Alfa

Criteria

Inclusion Criteria: - Subjects receiving multi-cycle chemotherapy for gynecological cancer

• Anemia due to chemotherapy (hgb less than or equal to 11.0 g/dL) - Expected to receive greater than or equal to 8 additional weeks of chemotherapy as part of their planned treatment - Karnofsky Performance Scale (KPS) greater than or equal to 50% - Adequate renal function - Adequate liver function Exclusion Criteria: - Iron deficiency - Known positive test for human immunodeficiency virus (HIV) infection